Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Is Not Associated with Neurological Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage

Overview

Journal Front Neurol

Specialty Neurology

Date 2017 May 2

PMID 28458650

Citations 5

Authors

Heikki Kiiski

Ville Jalkanen

Marika Ala-Peijari

Mari Hamalainen

Eeva Moilanen

Jukka Peltola

Jyrki Tenhunen

Affiliations

Soon will be listed here.

Abstract

Object: Aneurysmal subarachnoid hemorrhage (aSAH) is a common cause of death or long-term disability. Despite advances in neurocritical care, there is still only a very limited ability to monitor the development of secondary brain injury or to predict neurological outcome after aSAH. Soluble urokinase-type plasminogen activator receptor (suPAR) has shown potential as a prognostic and as an inflammatory biomarker in a wide range of critical illnesses since it displays an association with overall immune system activation. This is the first time that suPAR has been evaluated as a prognostic biomarker in aSAH.

Methods: In this prospective population-based study, plasma suPAR levels were measured in aSAH patients ( = 47) for up to 5 days. suPAR was measured at 0, 12, and 24 h after patient admission to the intensive care unit (ICU) and daily thereafter until he/she was transferred from the ICU. The patients' neurological outcome was evaluated with the modified Rankin Scale (mRS) at 6 months after aSAH.

Results: suPAR levels ( = 47) during the first 24 h after aSAH were comparable in groups with a favorable (mRS 0-2) or an unfavorable (mRS 3-6) outcome. suPAR levels during the first 24 h were not associated with the findings in the primary brain CT, with acute hydrocephalus, or with antimicrobial medication use during 5-days' follow-up. suPAR levels were associated with generally accepted inflammatory biomarkers (C-reactive protein, leukocyte count).

Conclusion: Plasma suPAR level was not associated with either neurological outcome or selected clinical conditions. While suPAR is a promising biomarker for prognostication in several conditions requiring intensive care, it did not reveal any value as a prognostic biomarker after aSAH.

Citing Articles

Soluble Urokinase-Type Plasminogen Activator Receptor and Inflammatory Biomarker Response with Prognostic Significance after Acute Neuronal Injury - a Prospective Cohort Study.

Sajanti A, Hellstrom S, Bennett C, Srinath A, Jhaveri A, Cao Y Inflammation. 2024; .

PMID: 39540961 DOI: 10.1007/s10753-024-02185-1.

The Role of Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Context of Aneurysmal Subarachnoid Hemorrhage (aSAH)-A Prospective Observational Study.

Schmidt T, Albanna W, Weiss M, Veldeman M, Conzen C, Nikoubashman O Front Neurol. 2022; 13:841024.

PMID: 35359651 PMC: 8960720. DOI: 10.3389/fneur.2022.841024.

Temporal patterns of inflammation-related proteins measured in the cerebrospinal fluid of patients with aneurysmal subarachnoid hemorrhage using multiplex Proximity Extension Assay technology.

Vlachogiannis P, Hillered L, Enblad P, Ronne-Engstrom E PLoS One. 2022; 17(3):e0263460.

PMID: 35324941 PMC: 8947082. DOI: 10.1371/journal.pone.0263460.

Admission Lower Serum Phosphate Ion Levels Predict Acute Hydrocephalus of Aneurysmal Subarachnoid Hemorrhage.

Zhang Y, Zheng S, Wang H, Chen G, Li C, Lin Y Front Neurol. 2022; 12:759963.

PMID: 35069408 PMC: 8773453. DOI: 10.3389/fneur.2021.759963.

Soluble Urokinase Plasminogen Activator Receptor Levels Correlation with Other Inflammatory Factors in Prognosis of Disability and Death in Patients with Ischemic Stroke.

Rozanski D, Szlufik S, Tomasiuk R, Milanowski L, Figura M, Saramak K Brain Sci. 2022; 12(1).

PMID: 35053782 PMC: 8774014. DOI: 10.3390/brainsci12010039.

References

Beschorner R, Schluesener H, Nguyen T, Magdolen V, Luther T, Pedal I . Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans. Neuropathol Appl Neurobiol. 2000; 26(6):522-7. DOI: 10.1046/j.0305-1846.2000.287.x. View

Roos Y, Levi M, Carroll T, Beenen L, Vermeulen M . Nimodipine increases fibrinolytic activity in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2001; 32(8):1860-2. DOI: 10.1161/01.str.32.8.1860. View

Sidenius N, Andolfo A, Fesce R, Blasi F . Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization. J Biol Chem. 2002; 277(31):27982-90. DOI: 10.1074/jbc.M111736200. View

Garcia-Monco J, Coleman J, Benach J . Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol. 2002; 129(1-2):216-23. DOI: 10.1016/s0165-5728(02)00186-8. View

Dumont A, Dumont R, Chow M, Lin C, Calisaneller T, Ley K . Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery. 2003; 53(1):123-33; discussion 133-5. DOI: 10.1227/01.neu.0000068863.37133.9e. View

Loch Macdonald R, Pluta R, Zhang J . Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol. 2007; 3(5):256-63. DOI: 10.1038/ncpneuro0490. View

Stevens R, Nyquist P . The systemic implications of aneurysmal subarachnoid hemorrhage. J Neurol Sci. 2007; 261(1-2):143-56. DOI: 10.1016/j.jns.2007.04.047. View

Nagai N, Okada K, Kawao N, Ishida C, Ueshima S, Collen D . Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke. Neurosci Lett. 2008; 432(1):46-9. DOI: 10.1016/j.neulet.2007.12.004. View

Pliyev B . Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem. 2008; 321(1-2):111-22. DOI: 10.1007/s11010-008-9925-z. View

10.

Olson F, Thurison T, Ryndel M, Hoyer-Hansen G, Fagerberg B . Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability. Clin Biochem. 2009; 43(1-2):124-30. DOI: 10.1016/j.clinbiochem.2009.09.028. View

11.

Thuno M, Macho B, Eugen-Olsen J . suPAR: the molecular crystal ball. Dis Markers. 2009; 27(3):157-72. PMC: 3835059. DOI: 10.3233/DMA-2009-0657. View

12.

Smith H, Marshall C . Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2009; 11(1):23-36. DOI: 10.1038/nrm2821. View

13.

Zacharia B, Hickman Z, Grobelny B, DeRosa P, Kotchetkov I, Ducruet A . Epidemiology of aneurysmal subarachnoid hemorrhage. Neurosurg Clin N Am. 2010; 21(2):221-33. DOI: 10.1016/j.nec.2009.10.002. View

14.

Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen T, Langkilde A . Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010; 268(3):296-308. DOI: 10.1111/j.1365-2796.2010.02252.x. View

15.

Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A . Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011; 15(1):R63. PMC: 3221996. DOI: 10.1186/cc10037. View

16.

Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J . Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med. 2011; 270(1):32-40. DOI: 10.1111/j.1365-2796.2011.02363.x. View

17.

Backes Y, van der Sluijs K, Tuip de Boer A, Hofstra J, Vlaar A, Determann R . Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study. Crit Care. 2011; 15(6):R270. PMC: 3388711. DOI: 10.1186/cc10550. View

18.

Zimmermann H, Koch A, Seidler S, Trautwein C, Tacke F . Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Liver Int. 2011; 32(3):500-9. DOI: 10.1111/j.1478-3231.2011.02665.x. View

19.

Persson M, Engstrom G, Bjorkbacka H, Hedblad B . Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. Atherosclerosis. 2011; 220(2):502-5. DOI: 10.1016/j.atherosclerosis.2011.10.039. View

20.

Fuhrman B . The urokinase system in the pathogenesis of atherosclerosis. Atherosclerosis. 2011; 222(1):8-14. DOI: 10.1016/j.atherosclerosis.2011.10.044. View